Wang, Yigang, Nauman Ahmad, Mitsuhiro Kudo, and Muhammad Ashraf. Contribution of Akt and endothelial nitric oxide synthase to diazoxide-induced late preconditioning. Am J Physiol Heart Circ Physiol 287: H1125-H1131, 2004. First published May 13, 2004; 10.1152/ajpheart.00183.2004.-The opening of mitochondrial ATP-sensitive K ϩ (mitoKATP) channels has a significant role in delayed ischemic preconditioning, and nitric oxide (NO) is a wellknown trigger for its activation. However, the source of NO remains unknown. Phosphorylation of endothelial NO synthase (eNOS) increases NO production and reduces apoptosis through the Akt signaling pathway. To elucidate the Akt signaling pathway involved in the opening and antiapoptotic effect of mitoK ATP channel during delayed pharmacological preconditioning, the mitoK ATP channel opener diazoxide (DE, 7 g/kg ip) alone or DE plus N -nitro-L-arginine methyl ester (L-NAME, 30 g/kg iv), an inhibitor of NOS, or wortmannin (WTN, 15 g/kg iv), an inhibitor of phosphatidylinositol 3Ј-kinase (PI3 kinase), was administered to wild-type (WT) or eNOS Ϫ/Ϫ mice during DE treatment. Twenty-four hours later, hearts were isolated and subjected to 40 min ischemia and 30 min reperfusion (I/R). The effect of DE and other interventions on hemodynamic, terminal dUTP nick-end labeling staining and biochemical changes during I/R was assessed in mouse hearts. Treatment with DE resulted in a 2.2-fold increase in phosphorylation of Akt and a significant increase in eNOS and inducible NOS (iNOS) proteins. Akt is upstream of NOS and the mitoK ATP channel as simultaneous pretreatment of WTN with DE abolished phosphorylation of Akt, which was not affected by L-NAME and 5-hydroxydecanoate. In hearts treated with DE, cardiac function was significantly improved after I/R, and apoptosis was also significantly decreased. WTN abolished the antiapoptotic effect of DE. Similarly, S-methylisothiourea, a specific iNOS inhibitor, when given to eNOS Ϫ/Ϫ mice that were pretreated with DE completely abolished the beneficial effects of DE on reduction of apoptotic death. DE was partially effective in eNOS Ϫ/Ϫ mice against the ischemic injury. It is concluded that DE activates Akt through the PI3 kinase signaling pathway and iNOS and eNOS is downstream of Akt. diazoxide; apoptosis NITRIC OXIDE (NO) is formed from L-arginine and oxygen by NO synthase (NOS), which is present in the coronary endothelium, endocardial endothelium, and cardiac myocytes (5). There are three known isoforms of NOS (13). Among them endothelial (eNOS), and neuronal cells (nNOS) are Ca 2ϩ dependent and remain inactive until intracellular calcium levels increase, resulting in enhanced calcium-calmodulin binding and subsequent activation (19), whereas the Ca 2ϩ -independent isoenzyme [inducible NOS (iNOS)] can be induced by cytokines (27) and other stimuli. Although NO is involved in late preconditioning (1, 24), it is still not clear which isoform is responsible for NO production, which serves as a trigger or mediator of preconditioning. Because the mitochondrial ATPsensitive K ϩ (mitoK ATP ) channel opener diazoxide (DE) elicits both early and late preconditioning (24) ] i increase may also upregulate eNOS leading to cardiac protection.
conditioning (1, 24) , it is still not clear which isoform is responsible for NO production, which serves as a trigger or mediator of preconditioning. Because the mitochondrial ATPsensitive K ϩ (mitoK ATP ) channel opener diazoxide (DE) elicits both early and late preconditioning (24) , it is reported that DE increases transient intracellular [Ca 2ϩ ] ( [Ca 2ϩ ] i ), which activates Ca 2ϩ -dependent protein kinase C (PKC) isoforms (22) and induces preconditioning in hearts (12) . This transient [Ca 2ϩ ] i increase may also upregulate eNOS leading to cardiac protection.
Apoptosis plays a key role in ischemia-reperfusion (I/R) injury (3) . Recently, it has been demonstrated that DE plays an important regulatory role in apoptotic cell death (20) . NO is also a key trigger of mitoK ATP channel activation (24) and is involved in the regulation of apoptosis (10) . High concentrations of NO produced from iNOS induce apoptosis, whereas low concentrations of NO produced from eNOS or pharmacological concentrations of exogenous NO released by NO donors reduce apoptosis (16) . Similarly, NO, which is generated upon ischemic stress, triggers the opening of mitoK ATP channel leading to cardioprotection (24) . A recent report showed that phosphatidylinositol 3Ј-kinase (PI3 kinase)-Akt played a role in eNOS phosphorylation and NO production (9) , which can also be induced by DE (2) . However, the relationship between the antiapoptotic effect of NO and DE-mediated stimulatory effects of NO are still unclear.
To study the contribution of endogenous NO to I/R damage without interference by pharmacological nonspecific inhibitors, eNOS knockout (eNOS Ϫ/Ϫ ) mice were used. The use of genetically manipulated mice is important due to nonspecific effects of pharmacological inhibitors currently in use, thus making less complex for the interpretation of data. The knockout animal model is therefore important to determine isoformspecific function of eNOS. To our knowledge, the present study is the first to utilize eNOS Ϫ/Ϫ mice to investigate the effect of both DE and NO in regulating apoptosis and late cardiac protection.
MATERIALS AND METHODS

Adult male eNOS
Ϫ/Ϫ (B6.129P2-Nos3 tm1Unc ) and wild-type (WT) mice weighing 25-30 g were obtained from Jackson Laboratory. The University of Cincinnati Animal Care and Use Committee approved the use of mice in these experiments.
Heart preparation. Mice weighing 25-30 g were anesthetized with pentobarbital sodium (40 mg/kg ip) and heparinized (5,000 U/kg) to protect the heart against microthrombi. The chest was opened at the sternum, and the heart was quickly removed and was then cannulated with a 20-gauge phalanged stainless steel cannula. Hearts were retro-gradely perfused through the aorta in a noncirculating Langendorff apparatus with Krebs-Henseleit buffer, which consisted of (in mM) 118 NaCl, 4.7 KCl, 1.2 MgSO4, 1.2 KH2PO4, 2.5 CaCl2, 25 NaHCO3, 0.5 Na-EDTA, and 11 glucose. The buffer was saturated with 95% O2-5% CO2 (pH 7.4, 37°C) for 50 min. Hearts were perfused at a constant pressure of 80 mmHg. A home-made water-filled balloon was inserted into the left ventricle and was adjusted to a left ventricular (LV) end-diastolic pressure (LVEDP) of 5-8 mmHg during initial equilibration. Thereafter, the balloon volume was not changed. The distal end of the catheter was connected to a Digi-Med Heart Performance Analyzer-(model 210, version 1.01, Micro-Med) via a pressure transducer (Case; Lakewood, CO). Hearts were paced at 350 beats/min except during ischemia. Pacing was reinitiated after 3 min of reperfusion in all groups. The index of myocardial function was determined as previously described (23 Experimental protocol. The study consisted of seven groups (Fig.  1) . After a 25-min equilibration period, hearts were subjected to 40 min of no-flow normothermic global ischemia and 30 min of reperfusion.
Measurement of lactate dehydrogenase. Lactate dehydrogenase (LDH), an indicator of myocardial tissue injury, was determined in the coronary effluent by a coupled-enzyme spectrometric technique (DU Series 500 Spectrophotometer, Beckman Instruments) by using a Sigma assay kit as described previously (21) . LDH was measured at 3, 5, 10, 20, and 30 min of reperfusion. The accumulated amount was obtained by integrating the area underneath the individual time course curve for 30 min of reperfusion.
Terminal dUTP nick end-labeling staining for the determination of myocardial apoptosis. Terminal dUTP nick-end labeling (TUNEL) assay was performed in deparaffinized 5-m for thick sections using a MEBSTAIN Apoptosis Kit II (Medical and Biological Laboratories). Sections from the mid left ventricle were stained for TUNEL, as previously described (20) . Sections were then stained with 4,6-diamidino-2-phenylindole to visualize nuclei and photographed with an Olympus BX41 microscope (Olympus America; Melville, NY) equipped with a digital camera.
Western blotting for iNOS and eNOS. Hearts were weighed and homogenized at 4°C with six bursts of 15 s each with a Polytron PT 20 in 1 ml RIPA buffer (1ϫ PBS, 1% Nonidat P-40, 0.5% sodium deoxycholate, 0.1% SDS, 10 mol/l PMSF, 30 l/ml aprotinin, and 100 mol/l sodium orthovanadate). Subsequently, the samples were centrifuged at 14,000 rpm for 10 min. The pellet was discarded, and the protein in the supernatant was determined. Standard SDS gel electrophoresis was performed with 20 g of protein loaded in each well of a 12% polyacrylamide gel. After electrophoresis, the proteins were transferred to a nitrocellulose membrane for 2 h at 100 V. The membrane was blocked with 5% no-fat dry milk in 1ϫ Tris-buffered saline containing 0.1% Tween 20 (0.1% TBST) for 1 h. The membrane was incubated with the primary iNOS and eNOS antibody (Santa Cruz, CA) at 1:1,000 dilution for 1 h at room temperature. After being washed with 0.1% TBST, the membrane was incubated with an anti-rabbit horseradish peroxidase-linked antibody (dilution, 1:500) for 1 h. The membranes were developed with enhanced chemiluminescence (Amersham) and exposed to X-ray film for the appropriate time.
Western blotting for Akt. Protein samples were mixed with equal volume of sample buffer to measure Akt kinase activity with the PhosphoPlus Akt [Ser-473] antibody kit (Cell Signaling Technology) as described previously (6) . The kit included a phosphospecific antibody that recognizes Akt only when phosphorylated at Ser-473, a control Akt antibody (phosphorylation-state independent), protein controls, and protein markers for Western blot analyses, plus reagents and protocols for the rapid analysis of Akt phosphorylation.
Statistical analysis. All values are expressed as means Ϯ SE. Group comparisons were analyzed by one-way ANOVA (Statview 4.0) followed by a Bonferroni-Dunn test. A value of P Ͻ 0.05 was considered to be statistically significant.
RESULTS
Preischemic cardiac hemodynamic parameters.
Preischemic baseline values of LV function in various treatment groups are summarized in Table 1 . The mean values of LV developed Values are means Ϯ SE; n, no. of animals. DE, diazoxide; eNOS Ϫ/Ϫ , endothial nitric oxide synthase knockout mice; L-NAME, N -nitro-L-arginine methy ester; SMT, S-methylisothiourea; WTN, wortmannin; LVDP, left ventricular (LV) diastolic pressure; LVEDP, LV end-diastolic pressure; CF, coronary flow. No significant differences were observed among the experimental groups (P Ͼ 0.05).
pressure (LVDP), LVEDP, and coronary flow (CF) were not significantly different among the groups. There was also no significant difference in the body and heart weights among the groups.
Postischemic cardiac hemodynamic parameters. The cardiac function was severely compromised in the ischemic control group. At the end of reperfusion, LVEDP rose significantly, whereas LVDP and CF were markedly reduced in the ischemic group compared with the control group (Fig. 2, A-C) . In addition, LDH leakage was also significantly increased in the ischemic group (Fig. 2D) .
Effect of DE on ischemic injury in WT hearts. Overall, postischemic LV contractile function was improved after DE pretreatment (Fig. 2) , as indicated by LVDP and CF, whereas the LVEDP was significantly decreased compared with ischemic control hearts. In DE-pretreated hearts, LDH leakage was also significantly reduced.
Effect of DE on ischemic injury in eNOS Ϫ/Ϫ mice. After pretreatment with DE, LVDP was significantly increased, whereas LVEDP was markedly reduced compared with ischemic control group. However, LVEDP did not rise significantly compared with the control ischemic group. No important changes in CF and LDH retention were observed in the eNOS gene-knockout mice compared with WT mice after I/R.
Pretreatment of eNOS Ϫ/Ϫ mice with S-methylisothiourea (SMT), a selective iNOS inhibitor, completely abolished the protective effect of DE, as indicated by decreased LVDP and CF and increased LVEDP and LDH release.
Similarly, pretreatment with N -nitro-L-arginine methyl ester (L-NAME), a nonselective NOS inhibitor, or Wortmannin (WTM), an inhibitor of PI3-kinase, blocked the cardiac protective effect of DE, as indicated by decreased LVDP and CF and increased LVEDP and LDH release (Fig. 2D) .
Effect of DE on eNOS and iNOS upregulation.
To determine whether DE upregulates eNOS and iNOS, Western blot analysis was performed. As shown in Fig. 3 , treatment with DE resulted in a time-dependent increase in eNOS and iNOS proteins reaching a peak at 12 h and leveling off after 24 h (Fig. 3, A and B) . However, eNOS activity was inhibited when hearts were pretreated with a general inhibitor of L-NAME, and eNOS synthesis was also prevented in eNOS Ϫ/Ϫ mice with SMT, a specific inhibitor of iNOS, but no effect on eNOS was observed in WT mice (Fig. 3C) .
Effect of diazoxide on Akt (protein kinase B)
. PI3-kinase generates phosphatidylinositol triphosphate, which activates Akt. DE pretreatment induced Akt phosphorylation, which was blocked by WTN, a PI3-kinase inhibitor. Akt phosphorylation was also activated in DE-pretreated hearts by L-NAME, a nonspecific inhibitor of NOS, or SMT, a rather specific inhibitor of iNOS. DE pretreatment in eNOS knockout mice also induced Akt phosphorylation (Fig. 4A) .
There was no difference in total Akt among the groups studied (Fig. 4B) . These results demonstrated that DE activates Akt through the PI3-kinase pathway. In fact, Akt phosphorylation was observed in all groups that were pretreated with NOS inhibitors, suggesting that NOS activation is downstream of Akt. Akt phosphorylation by DE was time dependent and peaked out at 24 h (Fig. 4C) . 5-Hydroxydecanoate did not block Akt phosphorylation induced by DE (Fig. 4D) .
Antiapoptotic effect of DE through NO signaling pathway. Because NO is an important trigger for the opening of mito-K ATP channels in DE-induced preconditioning, the source of NO production is not clear from previous studies. To ascertain whether eNOS was involved in the PI3 kinase-Akt-NO signaling pathway in the reduction of apoptosis, adult eNOS Ϫ/Ϫ mice were used to avoid further nonspecific effects of pharmacological inhibitors. In WT mice, an increased percentage of cells underwent apoptosis (Fig. 5) , although some studies report that the severity of an apoptosis is dependent on the period of reperfusion (3). Administration of DE markedly reduced TUNEL-positive cells. However, the percentage of apoptotic cells increased significantly in both eNOS Ϫ/Ϫ mice and mice treated with SMT, a specific inhibitor of iNOS, suggesting that eNOS and iNOS are the major source of NO during activation of Akt by DE. The antiapoptotic effect of DE was also abolished in the WT mice on pretreatment with L-NAME or WTN. These data provided further support to the concept that the PI3 kinase-Akt-NO pathway plays a critical role in the antiapoptotic effect of DE.
DISCUSSION
NO and intracellular signaling. NO plays an important role in the regulation of various normal developmental and physiological processes (8) . The intracellular signaling pathways by which DE causes eNOS upregulation are largely unresolved but may involve a series of events resulting in the transmission of the signal through the activation of PI3 kinase. This may result in the phosphorylation of Akt initiating the expression of eNOS and the release of NO. NO thus released is the most important modulator of vascular smooth muscle tone, especially in the coronary arteries, and the preservation of endothelial cell integrity and reduction in neutrophil infiltration (5) . NO has been suggested to modulate K ATP channels by increasing the second messenger cGMP. The cGMP-dependent protein kinases may be capable of phosphorylating K ATP channels and priming the channel to offer cardioprotection through coronary vasodilation and reduction in myocardial oxygen consumption via cGMP (25) . Recently, Sasaki et al. (17) confirmed this observation by demonstrating direct activation of the mitoK ATP channel with exogenously generated NO in myocytes. It has been shown that DE initiates PKC activation (21) , which provides a direct mechanistic link in pharmacological cardioprotection targeted at the mitoK ATP channel (7, 14) . Sasaki et al. (17) also reported that NO selectively activates mitoK ATP channels and enhances mitoK ATP channel opening already activated by DE. These channels, which are already open, appear to be more affected by the potentiating action of NO than those channels that are in the closed state. Exactly how opening of mitoK ATP channels confers protection by NO still remains unclear, but it is likely that opening of mitoK ATP channels reversibly inhibits cytochrome c oxidase, which is directly linked with apoptosis (26) . Opening of mitoK ATP channels also reduces intracellular Ca 2ϩ through the calcium uniporter (17) and reduces apoptosis (20) . Opening of mitoK ATP channel by DE also acts as a potential mechanism for early and delayed myocardial protection (24, 20, 14, 15) .
Apoptosis. This study demonstrates that Akt phosphorylation by DE is upstream of NOS, and both NOS and Akt phosphorylation are important in preventing cell death in the ischemic myocardium. However, despite Akt phosphorylation in eNOS Ϫ/Ϫ mice, partial protection by DE suggests that eNOS deletion is compensated by iNOS upregulation. In addition, administration of DE in eNOS Ϫ/Ϫ with SMT, a selective iNOS inhibitor, significantly diminished postischemic cardiac functional recovery, but without SMT, only partial protection was observed, suggesting that iNOS may be involved in DEinduced late preconditioning through a different signaling pathway from eNOS. It is not unreasonable to conclude that iNOS has more impact on functional recovery, whereas eNOS mediates apoptosis reduction. It became more clear when SMT was given to DE ϩ eNOS Ϫ/Ϫ mice, functional recovery was further reduced accompanied by an increase in apoptosis. eNOS is responsible for maintaining systemic blood pressure, vascular remodeling, and angiogenesis and is phosphorylated in response to various cellular stimuli (18) . It has recently been reported that eNOS is a novel substrate for Akt and that phosphorylation of eNOS by Akt results in calcium-independent NO production (4) . NO could modulate mitoK ATP channels and provide cardioprotection (11). Yang et al. (27) demonstrated that eNOS is expressed mainly in the coronary vasculature and endothelium, and it may function as a tissue protective factor against damage to the heart, which is consistent with our studies that DE upregulated eNOS proteins leading to antiapopototic effect through a PI3 kinase-Akt pathway. As mentioned above, treatment with DE significantly reduced myocardial apoptosis, as evidenced by reduced TUNEL-positive myocyte nuclei. Surprisingly, administration of DE to eNOS Ϫ/Ϫ mice or to WT mice together with SMT significantly reduced apoptosis. However, L-NAME was totally ineffective in preventing apoptosis, despite Akt activation. This suggests that Akt is upstream of NOS (Fig. 6) . Gao et al. reported (4) that treatment with L-NAME significantly reduced the antiapoptotic effect of insulin, whereas L-NAME alone only slightly increased the number of TUNEL-positive cells, suggesting that the basal production of NO during I/R is not sufficient to exert significant antiapoptotic effect in the myocardial tissue. Taken together, these results demonstrated that DE, an important agonist of mitoK ATP channel opener, exerts its antiapoptotic effect through the PI3 kinase-Akt pathway and that the phosphorylation of eNOS with subsequent NO production is an important downstream effector that contributes significantly to the cardioprotective effect of DE against myocardial I/R injury (Fig. 6) .
In the present study, the nonspecific effects of NOS inhibitors were avoided by using knockout mice, which provide a powerful tool in elucidating the cellular mechanisms of DE-or NO-induced preconditioning. On the other hand, pharmacological agents themselves may alter the cardiovascular response to various pathophysiological events, which emphasizes the complexity and difficulty in interpretation of the data. Thus NOS isoform-specific knockout mice could be a better animal model in understanding the basis of NO-induced cardiac protection against apoptosis and ischemic injury.
In summary, we have demonstrated that Akt and eNOS proteins are rapidly upregulated by DE and remain upregulated for at least 24 h. Thus NO and Akt could be the basis of protection in early and delayed preconditioning through PI3-kinase-dependent pathways.
